SCHEDULE: Millennium Management Group Discloses 5.6% Passive Stake in Tenax Therapeutics

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly disclosed a 5.6% beneficial ownership stake in Tenax Therapeutics, Inc. common stock.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G, indicating beneficial ownership of Tenax Therapeutics, Inc. Common Stock.
• Integrated Core Strategies (US) LLC beneficially owns 233,594 shares, representing 5.6% of the class.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 233,616 shares, also representing 5.6% of the class.
• All reporting persons hold shared voting and dispositive power over their respective beneficially owned shares.
• The acquisition of these securities was not for the purpose of changing or influencing the control of Tenax Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment regarding the issuer's performance or prospects. It simply reports a change in ownership structure.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by a prominent investment group like Millennium Management provides transparency regarding the ownership structure of Tenax Therapeutics, Inc. This can influence investor perception and potentially trading activity.

Key Dates

Keywords

Tenax Therapeutics, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Passive Stake